Polyclonal Antibody to Heparan Sulfate Proteoglycan (HSPG)
| Code | Size | Price |
|---|
| PAA565Hu01-20ul | 20ul | £81.00 |
Quantity:
| PAA565Hu01-100ul | 100ul | £149.00 |
Quantity:
| PAA565Hu01-200ul | 200ul | £200.00 |
Quantity:
| PAA565Hu01-1ml | 1ml | £454.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SDC2; HSPG1; SYND2; Fibroglycan; Syndecan 2; Syndecan Proteoglycan 2; Heparan Sulfate Proteoglycan 1,Cell Surface-Associated; Heparan Sulphate Proteoglycan
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Heparan Sulfate Proteoglycan
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
www.ncbi.nlm.nih.gov/pubmed/26024383; https://www.ncbi.nlm.nih.gov/pubmed/28589943;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Heparan Sulfate Proteoglycan (HSPG) | RPA565Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||